The predictive utility of circulating PCSK9 levels on diabetes mellitus
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-021-01226-5
Abstract: Increasing data including ours have suggested that proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel regulator of cholesterol metabolism, may also play an important role in the development of type 2 diabetes mellitus (T2DM) and… read more here.
Keywords: t2dm; pcsk9 levels; diabetes mellitus; pcsk9 ... See more keywords
Circulating PCSK9 in Statin-Treated Patients with Type 2 Diabetes Mellitus (T2DM)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2217-pub
Abstract: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a natural circulating inhibitor of the LDL receptor. There is evidence that PCSK9 is a risk factor for coronary artery disease. In this study we aimed to determine… read more here.
Keywords: statin; statin treated; pcsk9; circulating pcsk9 ... See more keywords
Sex difference in circulating PCSK9 and its clinical implications
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.953845
Abstract: Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs). Beyond the regulation of circulating LDL-C, PCSK9 also… read more here.
Keywords: circulating pcsk9; clinical implications; difference circulating; sex difference ... See more keywords